Physician Assistant in Winnetka, CA Accepting Medicare

2 Physician Assistant nurses found. Showing 1 - 2

Eric David Laviaddin, PA Physician Assistant Medicare: Accepting Medicare Assignments Practice Location: 20800 Sherman Way, Winnetka, CA 91306 Phone: 818-883-2273

Humberto Jose Barboza, PA Physician Assistant Medicare: Medicare Enrolled Practice Location: 20800 Sherman Way, Winnetka, CA 91306 Phone: 818-883-2273

News Archive

Circassia commences Phase II trials of its T-cell vaccines against house dust mite and cat allergies

Circassia Ltd, a specialty biopharmaceutical company focused on allergy, today announced that it has initiated phase II clinical trials of its T-cell vaccines targeting house dust mite and cat allergies. With the start of these studies, and the ongoing trial of Circassia's ragweed allergy (hay fever) T-cell vaccine, the company now has three clinical development programmes in phase II.

European scientists expect to begin human trials using pharmaceuticals grown in GM plants

The European Union has awarded €12 million to a network of scientists in 11 European countries and South Africa and the aim is to use plants to produce vaccines and treatments against major diseases including AIDS, rabies, diabetes and TB.

Massage can enhance healing and strength of muscles, study finds

Massage has been used to treat sore, injured muscles for more than 3,000 years, and today many athletes swear by massage guns to rehabilitate their bodies. But other than making people feel good, do these "mechanotherapies" actually improve healing after a severe injury? According to a new study from researchers at Harvard's Wyss Institute for Biologically Inspired Engineering and John A. Paulson School of Engineering and Applied Sciences (SEAS), the answer is "yes."

Lipid Therapeutics to proceed with US LT-02 Phase III trial for mild-moderate ulcerative colitis

Lipid Therapeutics announces today that it has successfully filed its first US IND for its lead product LT-02 and is now in a position to proceed with a planned Phase III trial in the US in mild-moderate ulcerative colitis patients. The LT-02 IND was subject to the FDA's customary 30 day review period.

Read more Medical News

› Verified 3 days ago